Document ID: chunk:federal_register_of_legislation:F2025L00049:schedule:4:p15
Version: federal_register_of_legislation:F2025L00049
Segment Type: schedule
Provision Reference: sch 4 (pt 15/22)
Character Range: 226423–229984

human therapeutic use.
NITROFURANTOIN.
NITROFURAZONE.
NITROUS OXIDE for therapeutic use.
NITROXOLINE.
NIVOLUMAB.
NIZATIDINE except when included in Schedule 2.
NOMEGESTROL.
NOMIFENSINE.
NORADRENALINE.
# 19‑NORANDROSTENEDIOL.
# 19‑NORANDROSTENEDIONE.
# NORANDROSTENOLONE.
# NORBOLETHONE.
# NORCLOSTEBOL.
NORELGESTROMIN.
# NORETHANDROLONE.
NORETHISTERONE.
NORFLOXACIN.
NORGESTREL.
NORIBOGAINE.
NORMAL HUMAN IMMUNOGLOBULIN.
# NORMETHANDRONE.
NORTRIPTYLINE.
NOVOBIOCIN.
NOXIPTYLINE.
NUSINERSEN.
NYSTATIN except when included in Schedule 2 or 3.
OBETICHOLIC ACID.
OCLACITINIB.
OCRELIZUMAB.
OCRIPLASMIN.
OCTAMYLAMINE.
OCTATROPINE.
OCTREOTIDE.
OCTYL NITRITE.
ODEVIXIBAT.
OFATUMUMAB.
OFLOXACIN.
OLANZAPINE.
OLAPARIB.
OLARATUMAB.
OLEANDOMYCIN except:
 (a) when included in Schedule 5; or
 (b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.
OLEANDRIN.
OLIPUDASE ALFA.
OLMESARTAN.
OLODATEROL.
OLOPATADINE except when included in Schedule 2.
OLSALAZINE.
OMALIZUMAB.
OMBERACETAM.
OMBITASVIR.
OMEGA‑3‑ACID ETHYL ESTERS (excluding salts and derivatives) for human therapeutic use, for the treatment of post‑myocardial infarction and/or hypertriglyceridaemia.
OMEPRAZOLE except when included in Schedule 2 or 3.
ONASEMNOGENE ABEPARVOVEC.
ONDANSETRON.
OPICAPONE.
OPIPRAMOL.
ORBIFLOXACIN.
ORCIPRENALINE.
ORGANOPHOSPHORUS COMPOUNDS with anticholinesterase activity for human therapeutic use except:
 (a) when separately specified in these Schedules; or
 (b) in preparations containing 2% or less of malathion for external use.
ORLISTAT except when included in Schedule 3.
ORNIDAZOLE.
ORNIPRESSIN.
ORPHENADRINE.
ORTHOPTERIN.
OSELTAMIVIR.
OSILODROSTAT.
OSIMERTINIB.
OUABAIN.
# OVANDROTONE.
# OXABOLONE.
OXACILLIN.
OXALIPLATIN.
# OXANDROLONE.
OXAPROZIN.
# OXAZEPAM.
OXCARBAZEPINE.
OXEDRINE for human internal use except in preparations labelled with a recommended daily dose of 30 mg or less of oxedrine.
OXETACAINE (oxethazaine) except when included in Schedule 2.
OXICONAZOLE except:
 (a) when included in Schedule 2 or 3; or
 (b) in preparations for the treatment of tinea pedis.
OXIRACETAM.
OXITROPIUM.
OXOLAMINE.
OXOLINIC ACID.
OXPRENOLOL.
OXYBUPROCAINE.
OXYBUTYNIN.
# OXYMESTERONE.
# OXYMETHOLONE.
OXYPHENBUTAZONE.
OXYPHENCYCLIMINE.
OXYPHENONIUM.
OXYTETRACYCLINE except when included in Schedule 5.
OXYTOCIN.
OZANIMOD.
PACLITAXEL.
PALBOCICLIB.
PALIFERMIN.
PALIPERIDONE.
PALIVIZUMAB.
PALONOSETRON.
PALOPEGTERIPARATIDE.
PALOVAROTENE.
PAMAQUIN.
PAMIDRONIC ACID (includes pamidronate disodium).
PANCREATIC ENZYMES except:
 (a) in preparations containing 20,000 BP units or less of lipase activity per dosage unit; or
 (b) when separately specified in these Schedules.
PANCURONIUM.
PANITUMUMAB.
PANOBINOSTAT.
PANTOPRAZOLE except when included in Schedule 2 or 3.
PAPAVERINE in preparations for injection.
PARACETAMOL:
 (a) when combined with aspirin or salicylamide or any derivative of these substances except when separately specified in these Schedules; or
 (b) when combined with ibuprofen in a primary pack containing more than 30 dosage units; or
 (c) in modified release tablets or capsules containing more than 665 mg paracetamol; or
 (d) in non‑modified release tablets or capsules containing more than 500 mg paracetamol; or
 (e) in individually wrapped powders or sachets of granules each containing more than 1000 mg paracetamol; or
 (f) in tablets or capsules enclosed in a primary pack containing more than 100 tablets or capsules except in Schedule 3; or
 (g) in individually wrapped powders or sachets of granules enclosed